证券代码：603439 证券简称：贵州三力 公告编号：2025-037 贵州三力制药股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.34元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放 | | --- | --- | --- | --- | --- | | | | | | 日 | | Ａ股 | 2025/6/25 | － | 2025/6/26 | 2025/6/26 | 差异化分红送转： 是 一、通过分配方案的股东大会届次和日期 根据《上海证券交易所上市公司自律监管指引第 7 号—回购股份》的规定， 公司存放于回购专用证券账户的股份不参与本次利润分配。公司本次不参与利润 分配的股份数4,982,200股（回购专用账户中的4,190,200股及待回购注销的792,000 股）。 3. 差异化分红送转方案： （1）差异化分红方案 公司本次利润分配实施时股本总数为 409,802,216 ...

Group 1 - Company GuoDeWei plans to repurchase shares with a total investment of between 100 million to 150 million yuan, with a maximum repurchase price of 53 yuan per share, expecting to buy back between 1.89 million to 2.83 million shares, accounting for 0.78% to 1.17% of total share capital [1] - Company Shuangliang Energy has won a bid for the Gansu Energy Chemical Qinyang 2×660MW coal power project, with a total bid amount of 237 million yuan, representing 1.82% of the company's projected revenue for 2024 [1] - Company China Pacific Insurance reported a total premium income of 227.17 billion yuan from its two subsidiaries in the first five months, with a year-on-year growth of 10.2% for its life insurance subsidiary and 0.5% for its property insurance subsidiary [1][2] Group 2 - Company LuKang Pharmaceutical has received a drug registration certificate for injectable Cefoperazone Sodium, a third-generation cephalosporin with broad-spectrum antibacterial properties [3] - Company 吉祥航空 reported a 4.97% year-on-year increase in passenger turnover in May, with a seat occupancy rate of 86.14%, up 3.70% year-on-year [4][5] - Company DuRui Pharmaceutical's subsidiary has also received a drug registration certificate for injectable Cefoperazone Sodium [6] Group 3 - Company KeLan Software announced that part of the shares held by its controlling shareholder will be auctioned, involving 5.09 million shares, accounting for 1.07% of the total share capital [7] - Company HuaCan Optoelectronics received a government subsidy of 87.84 million yuan, which is expected to positively impact the company's pre-tax profit for 2025 [8] - Company JinZhi Technology has won a bid for projects from the State Grid and China Resources New Energy, with a total bid amount of 84.41 million yuan [9] Group 4 - Company Vision China completed a capital increase for its subsidiary, raising 100 million yuan to accelerate its layout in the AI field [11] - Company Youa Co. received a profit distribution of 96.03 million yuan from its investment in Changsha Bank [13] - Company WanBangde's subsidiary obtained a patent for a deuterated compound, enhancing the chemical stability and reducing toxicity [16] Group 5 - Company DongCheng Pharmaceutical completed the enrollment of all 488 participants in the Phase III clinical trial for Fluorine-18 PSMA peptide injection, aimed at prostate cancer diagnosis [17] - Company China Merchants Expressway announced that its first phase of medium-term notes for 2024 will pay interest on July 2, 2025, with a total issuance of 2.5 billion yuan and an interest rate of 2.35% [18] - Company JinPu Titanium's subsidiary has temporarily suspended production for maintenance due to falling product prices and high production costs [20] Group 6 - Company BeiLu Pharmaceutical received a marketing authorization for Iodinated Contrast Injection in Hungary, marking another approval in the EU [22] - Company LiXing Co. obtained an overseas investment certificate for its wholly-owned subsidiary in Singapore, with a total investment of 2.16 million yuan [24] - Company LangKun Technology won a garbage collection service project with a bid amount of 21.57 million yuan [26] Group 7 - Company KeRui International plans to transfer 55% of its subsidiary Tianjin ZhiRui's equity for 41.96 million yuan [28] - Company Nanjing JuLong intends to invest 130 million yuan to build a production project for special materials with an annual output of 40,000 tons [30] - Company NanShan Intelligent plans to use up to 50 million yuan of idle funds for cash management in safe and liquid financial products [32] Group 8 - Company GuangLian Aviation completed the business change registration for its subsidiary, involving the introduction of strategic investors [34] - Company XiaoFang Pharmaceutical signed a cooperation agreement to develop a new drug for hair loss treatment [36] - Company GuiZhou SanLi plans to sign a 150 million yuan technology transfer and development contract with Guangdong Pharmaceutical University [38] Group 9 - Company ST SiLong's subsidiary received a drug registration certificate for Famotidine injection, used for treating upper gastrointestinal bleeding [52] - Company ZhongKe Information's executive plans to reduce holdings of up to 180,000 shares, accounting for 0.06% of total share capital [53] - Company KeLun Pharmaceutical's injectable Cefoperazone Sodium/Chloride Sodium injection received drug registration approval [54] Group 10 - Company LuXin Investment plans to transfer 10.06% of its stake in LuXin HuiJin for 203 million yuan, aiming to focus on its main business [56] - Company Western Gold plans to acquire 100% of Xinjiang MeiSheng for 1.655 billion yuan [58] - Company JinTou City Development intends to swap assets worth 5.862 billion yuan, changing its main business to urban centralized heating [60]

Group 1 - Xiaofang Pharmaceutical announced a collaboration with Shanghai Skin Disease Hospital to develop a new traditional Chinese medicine for hair loss, Compound Cèbǎi Tincture, which is expected to be the first TCM formulation for hair loss in China [1] - Guizhou Sanli plans to invest 150 million RMB in a patent transfer and technical cooperation contract with Guangdong Pharmaceutical University for the development of a new TCM drug [1] - The technical cooperation will involve a total development cost of 100 million RMB for the research and development of SL&GDPU-001, a new TCM drug [2] Group 2 - Jichuan Pharmaceutical's actual controller, Cao Longxiang, transferred part of his equity in Jichuan Holdings to his son, Cao Fei, which is an internal family equity adjustment and will not affect the company's independence [2] - Junshi Biosciences received acceptance for the clinical trial application of JT118 injection, a vaccine aimed at preventing monkeypox virus infection, marking a significant step as no such vaccine has been approved in China [3] - Palin Bio announced that its controlling shareholder, Shengbang Yinghao, intends to transfer 21.03% of its shares to China National Pharmaceutical Group, which will result in a change of control [3] Group 3 - East China Pharmaceutical's subsidiary received FDA approval for the clinical trial of HDM1010 tablets, aimed at treating type 2 diabetes, enhancing the company's competitiveness in the endocrine field [4]

Group 1 - Guizhou Sanli plans to sign a technology transfer and development contract with Guangdong Pharmaceutical University, with a total contract amount of RMB 150 million [1] - The technology contract involves the transfer of a patent for the use of Jinlv Banfenghe in the preparation of drugs for liver injury prevention and treatment, along with other related patents [1][2] - The patent transfer was successfully completed for RMB 50 million, with the transaction taking place on June 11, 2025 [1] Group 2 - The contract stipulates an overall transfer fee of RMB 50 million for the patent rights, with an initial payment of RMB 5 million due within 10 working days after signing [2] - The total development cost for the technical cooperation is RMB 100 million, with payments to be made in installments based on contract terms [2]

Core Viewpoint - Guizhou Sanli Pharmaceutical Co., Ltd. plans to sign technology transfer and development contracts with Guangdong Pharmaceutical University to enhance its product portfolio and market competitiveness through collaboration in drug research and development [1][5]. Group 1: Contract Overview - The company intends to sign a technology transfer contract for a fibrosis invention patent, successfully acquiring it for RMB 50 million on June 11, 2025 [2][3]. - The total amount for the proposed technology contracts is RMB 150 million, which is close to the board's review and disclosure threshold, prompting the management to voluntarily disclose this information [2][5]. - The company held board meetings on June 12, 2025, to approve the contracts, which do not require shareholder approval or constitute a major asset restructuring [2][5]. Group 2: Contract Details - The technology transfer contract involves the transfer of rights for the invention patent related to liver protection and fibrosis treatment, with the company becoming the sole patent owner [3][4]. - The payment structure for the patent transfer includes an initial payment of RMB 5 million within 10 working days after signing, followed by milestone-based payments [3][4]. - The technology development contract focuses on the joint development of SL&GDPU-001, a new traditional Chinese medicine, covering non-clinical and clinical research phases [4][5]. Group 3: Impact on the Company - The collaboration aims to leverage the company's industrial capabilities and the university's research resources, aligning with the company's long-term strategic goals [5]. - The contracts are not expected to significantly impact the company's current financial status or operating performance, with future impacts dependent on the progress of the projects [5].

Group 1 - The core point of the announcement is that the company plans to sign a technology transfer and development contract with Guangdong Pharmaceutical University to enhance its product portfolio and market competitiveness through collaboration [1][2] - The total amount of the proposed technology contract is 150 million RMB, which will be paid in installments according to the contract terms [2] - The signing of the contract does not require approval from the shareholders' meeting and does not constitute a related party transaction or a major asset restructuring as per relevant regulations [2] Group 2 - The decision was made during the 12th meeting of the 4th Supervisory Board, which was held in compliance with legal and regulatory requirements [1] - The voting results showed unanimous support with 3 votes in favor, and no votes against or abstaining [2] - The contract aligns with the company's long-term strategic goals and is expected to have no significant impact on the current financial status or operating performance [2]

证券代码：603439 证券简称：贵州三力 公告编号：2025-034 贵州三力制药股份有限公司 关于拟与广东药科大学签署技术转让合同 及技术开发（合作）合同的自愿性信息披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 特别提示： 一、合同签署概况 贵州三力制药股份有限公司（以下简称："贵州三力"或"公司"）近日拟 与广东药科大学签署《技术转让（专利权/专利申请权）合同》（以下简称"技 1 本次公司拟签署的《技术转让（专利权/专利申请权）合同》及《技术开发 （合作）合同》（以下合并简称"技术合同"）系确立双方合作意向，具体 实施进度和最终成果尚存在不确定性，敬请广大投资者谨慎决策，注意投资 风险。 本次拟签署的技术合同总金额为人民币 1.5 亿元，虽未达到公司董事会审议 及信息披露标准，因金额接近审议及披露标准，且本事项涉及公司长期发展 战略布局，出于谨慎性原则公司管理层决定提交董事会审议，并进行自愿信 息披露。 已履行的审议程序：公司于 2025 年 6 月 12 日召开了第四届董事会第十三次 会议和第四届监事会第十 ...

证券代码：603439 证券简称：贵州三力 公告编号：2025-036 二、监事会会议审议情况 会议以记名投票表决方式，审议通过了如下议案： （一）审议通过了《关于公司拟与广东药科大学签署技术转让合同及技术 开发（合作）合同的议案》 公司拟与广东药科大学签署《技术转让（专利权/专利申请权）合同》及《技 术开发（合作）合同》（以下合并简称"技术合同"），本次合作，旨在通过整 合公司产业化能力与高校研发资源，推动创新药物科研成果转化，助力公司拓展 产品布局，提升公司市场竞争优势。 本次拟签署的技术合同总金额为 1.5 亿元人民币，公司将依据技术合同约定 支付方式分期支付费用。根据《公司章程》及公司相关制度的规定，本次合同的 签署不需要提交公司股东大会审议。本次合同的签订不构成关联交易，亦不构成 贵州三力制药股份有限公司 第四届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 2025 年 06 月 12 日，贵州三力制药股份有限公司（以下简称"贵州三力" "公司"）第四届监事会第十 ...

证券代码：603439 证券简称：贵州三力 公告编号：2025-035 贵州三力制药股份有限公司 第四届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 2025 年 06 月 12 日，贵州三力制药股份有限公司（以下简称"贵州三力" "公司"）第四届董事会第十三次会议在公司会议室以现场和通讯表决方式召开。 本次会议的会议通知和材料于 2025 年 06 月 04 日以书面及通讯等方式送达所有 参会人员。本次会议应到董事 9 人，实到董事 9 人。本次会议由董事长张海先生 召集和主持，本次会议无列席人员。会议的召开符合有关法律、行政法规、部门 规章、规范性文件和《公司章程》的有关规定，会议决议合法有效。 二、董事会会议审议情况 会议以记名投票表决方式，审议通过了如下议案： （一）审议通过了《关于公司拟与广东药科大学签署技术转让合同及技术 开发（合作）合同的议案》 公司拟与广东药科大学签署《技术转让（专利权/专利申请权）合同》及《技 术开发（合作）合同》（以下合并简称"技术合同" ...

贵州三力（SH 603439，收盘价：12.34元）6月11日晚间发布公告称，截至本报告披露日，贵州三力制 药股份有限公司持股5%以上股东海南悦欣医药投资合伙企业（普通合伙）持有公司股份2100万股，占 公司总股本的约5.12%；公司副董事长、总经理、董事会秘书张千帆持有公司股份约71万股，占公司总 股本的0.1744%；公司董事、副总经理王毅持有公司股份约134万股，占公司总股本的0.3258%；公司副 总经理余渊持有公司股份约32万股，占公司总股本的0.0793%；公司副总经理罗战彪持有公司股份37万 股，占公司总股本的0.0903%。持股5%以上股东海南悦欣医药投资合伙企业（普通合伙）因自身业务需 求，拟从2025年7月3日至2025年10月2日期间，通过集中竞价交易方式减持其所持有的公司股份合计不 超过约205万股。公司副董事长、总经理、董事会秘书张千帆因个人资金需求，拟从2025年7月3日至 2025年10月2日期间，通过集中竞价交易方式减持其所持有的公司股份合计不超过约18万股。公司董 事、副总经理王毅因个人资金需求，拟从2025年7月3日至2025年10月2日期间，通过集中竞价交易方式 减持其所 ...